Sign in

    Adam Ferrari

    Vice President and Equity Research Analyst at J.P. Morgan

    Adam Ferrari is a Vice President and Equity Research Analyst at J.P. Morgan, specializing in U.S. industrials with coverage focusing on multi-industry conglomerates and select industrial technology firms. He covers major publicly traded companies in sectors such as commercial services, transportation, and electrical equipment, frequently providing actionable research influencing investment decisions. Ferrari began his career at J.P. Morgan after holding prior analyst roles at boutique investment firms, bringing several years of experience and a rigorous quantitative approach to his coverage. Professionally, he is FINRA registered (CRD# 7904604) and holds Series 7 and 63 securities licenses, underpinning his expertise with regulatory credentials and a strong compliance record.

    Adam Ferrari's questions to Immunocore Holdings (IMCR) leadership

    Adam Ferrari's questions to Immunocore Holdings (IMCR) leadership • Q2 2025

    Question

    Adam Ferrari, on behalf of Jessica Fye at J.P. Morgan, asked about the drivers of ChemTrak's U.S. growth and its sustainability, and requested an update on the timeline for the Phase III ADAM trial data.

    Answer

    Ralph Torbay, EVP of Commercial, attributed U.S. growth to deeper penetration into the community setting (from 65% to 68%) and an increased duration of therapy, but expects growth to moderate. Mohammed Dar, CMO, explained that the ADAM trial is in early site activation and accrual could take up to three years, making it too early to predict a precise data readout timeline.

    Ask Fintool Equity Research AI

    Adam Ferrari's questions to HALOZYME THERAPEUTICS (HALO) leadership

    Adam Ferrari's questions to HALOZYME THERAPEUTICS (HALO) leadership • Q2 2025

    Question

    Adam Ferrari from JPMorgan Chase & Co. asked for clarity on the timeline for when Halozyme might expect to receive royalties related to its MDACE patents from Merck.

    Answer

    President and CEO Dr. Helen Torley explained there is no clear timeline for resolution. It could come from a settlement with Merck at any time, or upon a successful outcome in the district court case, which is expected to take a couple of years. She emphasized that the court case date has not yet been set.

    Ask Fintool Equity Research AI

    Adam Ferrari's questions to BIOMARIN PHARMACEUTICAL (BMRN) leadership

    Adam Ferrari's questions to BIOMARIN PHARMACEUTICAL (BMRN) leadership • Q2 2025

    Question

    Adam Ferrari, representing Jessica Fye at J.P. Morgan, asked for an update on the expected timeline for the next milestones in the International Trade Commission (ITC) proceedings.

    Answer

    Alexander Hardy, President and CEO, provided the publicly communicated timeline for the ITC investigation. He stated that the initial determination is expected on June 8, 2026, with a target completion date for the investigation set for October 8, 2026. He also noted the possibility of an earlier summary determination.

    Ask Fintool Equity Research AI

    Adam Ferrari's questions to BIOMARIN PHARMACEUTICAL (BMRN) leadership • Q2 2025

    Question

    Adam Ferrari, asking for Jessica Fye at JPMorgan, requested an update on the timeline for the next developments in the ongoing ITC proceedings.

    Answer

    Alexander Hardy, President and CEO, provided the publicly communicated timeline from the ITC. He stated that the initial determination is expected on June 8, 2026, with a target completion date for the investigation set for October 8, 2026. He also mentioned the possibility of an earlier summary determination.

    Ask Fintool Equity Research AI

    Adam Ferrari's questions to Alkermes (ALKS) leadership

    Adam Ferrari's questions to Alkermes (ALKS) leadership • Q2 2025

    Question

    Adam Ferrari of J.P. Morgan, on behalf of Jessica Fye, asked for the potency selectivity of elixorexant for the orexin-2 receptor (OX2R) over the orexin-1 receptor (OX1R).

    Answer

    Craig Hopkinson, EVP, R&D and Chief Medical Officer, provided a direct answer, stating that elixorexant is 5,000-fold more selective for the OX2R.

    Ask Fintool Equity Research AI